97 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2026 in Colorado to deliver a full suite of premium, scalable and customizable manufacturing solutions. Agilent Advanced Therapeutics’ CDMO portfolio includes oligonucleotides, microbial fermentation, complex and synthetic chemistry, bioreagents, highly potent APIs, and cell line development. The integrated platform provides customers streamlined access to end-to-end development and manufacturing services through a single partner — from discovery and process development through clinical- and commercial-scale manufacturing. “The Agilent Advanced Therapeutics solution strengthens our ability to support our customers and reinforces our long-term commitment to growth, investment, and leadership in this space,” said Agilent President and CEO, Padraig McDonnell. “For our customers, this means a more integrated experience, deeper technical partnership and a trusted team that understands what it takes to bring life-changing therapies to patients.” Simon May, president of Agilent’s Life Sciences and Diagnostics Markets Group, added: “This launch reflects the combined excellence of our teams and our commitment to advancing the next generation of therapies. We are excited to bring our unified Agilent Advanced Therapeutics capabilities to partners around the world.” NEWS Piramal Pharma Solutions’ Grangemouth, UK facility successfully delivers 1,500th ADC batch Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA | BSE: 543635), is proud to announce the completion of the 1,500th antibody-drug conjugate (ADC) batch at its dedicated bioconjugate development and manufacturing facility in Grangemouth, UK. With the 1500th batch representing a commercial oncology ADC batch, this milestone highlights the Company’s cutting-edge capabilities and unwavering commitment to Patient Centricity. For over two decades, Piramal Pharma Solutions has been a global leader in ADC development and manufacturing. As the first FDA-approved ADC CDMO and the first CDMO to commercially manufacture an ADC, Piramal demonstrates unmatched proficiency in this segment. Piramal leverages this expertise to provide a comprehensive range of integrated ADC solutions from Grangemouth, spanning from proof-of-concept studies to clinical- and commercial-scale manufacturing. These capabilities make the site an essential part of the ADCelerate™ program, Piramal’s rapid, integrated phase I ADC program. With seamless tech transfers supported by strong Program Management, Technical, and Quality teams, the program combines the specialized capabilities at Grangemouth with those across Piramal’s global network to streamline the path from R&D to GMP production. Building on Piramal’s history of ADC leadership, Grangemouth has developed hundreds of unique bioconjugates and has now successfully manufactured 1,500 ADC batches, including clinical, commercial, and non-GMP batches. But the facility isn’t just backed by legacy; it’s also supported by the Science Collective’s subject matter experts, who provide technical insight and strategic direction to guide projects to success. In alignment with Piramal’s commitment to quality, Grangemouth maintains a strong regulatory record, including accreditations from the US FDA and MHRA. With its unparalleled expertise and advanced solutions, the facility enables Piramal to deliver lifesaving bioconjugate therapies to patients in need with speed, precision, and quality. The Grangemouth Patient Awareness Council (PAC) introduced NumBear to reinforce its slogan, “It’s not just numbers, they are people.” NumBear is more than just a mascot; he’s a visual reminder that everything the site does is ultimately for the patient — behind every batch number is a person waiting for a life-changing medicine.
RkJQdWJsaXNoZXIy MjY2OTA4MA==